BVAXF
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q3 | -0.03 | $0 | -$1M |
| 2025 Q2 | -0.05 | $0 | -$1M |
| 2025 Q1 | -0.04 | $0 | -$892,645 |
| 2024 Q4 | -0.13 | $0 | -$1M |
| 2024 Q3 | -0.05 | $0 | -$412,198 |
| 2024 Q2 | -0.03 | $0 | -$436,932 |
| 2024 Q1 | 0.04 | $0 | $2,382 |
| 2023 Q4 | -0.25 | $0 | -$2,020 |